Search Results

109 Results for "biomeafusion".

Sort By

Press Releases

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025
·
1 min read
Press Releases

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

December 16, 2024
·
1 min read
Press Releases

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

January 14, 2025
·
8 min read
Press Releases

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - December 2, 2024

December 3, 2024
·
1 min read
Press Releases

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

October 22, 2024
·
4 min read
Press Releases

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

December 6, 2024
·
6 min read
Press Releases

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - November 1, 2024

November 4, 2024
·
1 min read
Press Releases

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

October 15, 2024
·
4 min read
Press Releases

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

January 8, 2025
·
9 min read
Press Releases

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

December 10, 2024
·
9 min read